CTRI/2024/02/062929
Completed
Phase 4
A post market clinical follow up prospective study to evaluate safety and performance of Sodium Hyaluronate 0.2% Eye Drops - NI
Overview
- Phase
- Phase 4
- Intervention
- Not specified
- Conditions
- Health Condition 1: H579- Unspecified disorder of eye and adnexa
- Sponsor
- Amanta Healthcare Limited
- Enrollment
- 54
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Subjects who are able to give voluntary, written informed consent to participate in this study.
- •Subjects who experience eye dryness, Eye Soreness/ burning, Irritative Sensation, Eye fatigue, contact lens caused dryness, discomfort of eyes due to the continuous use of computer/ TV/
- •exposed pollution/ dry environment
Exclusion Criteria
- •Anyone with known allergic reaction to Sodium Hyaluronate 0\.2% Eye Drops.
- •Subjects with existing eye infection
- •History of ocular surgery. History or active signs of severe or serious ocular conditions such as inflammatory corneal ulcers, recurrent erosions, and uveitis at any time
- •Patients participating in any another clinical trial during study
- •Pregnant/lactating women during study period.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Phase 4
A study to evaluate safety and performance of Hydroxypropyl Methylcellulose Eye DropsCTRI/2024/06/069121Kilitch Healthcare India Ltd.
Not yet recruiting
Phase 4
A study to evaluate safety and performance of Sodium Hyaluronate Ophthalmic SolutioCTRI/2024/06/068514Kilitch Healthcare India Ltd.
Completed
Phase 4
The purpose of the study is to evaluate safety and performance of Eye Preparations - Sodium Chloride Eye Drop (0.75%) (Calendula extract plus Hamamelis extractHealth Condition 1: H28- Cataract in diseases classified elsewhereCTRI/2022/07/043790STERICON PHARMA PRIVATE LIMITED72
Completed
Phase 4
The purpose of the study is to evaluate safety and performance of Eye Preparations - HPMC EYE WASH (Hydroxy Propyl Methyl Cellulose Eye Wash )Health Condition 1: H28- Cataract in diseases classified elsewhereCTRI/2022/07/043794STERICON PHARMA PRIVATE LIMITED72
Completed
Phase 4
the study is to evaluate safety and performance of Eye Preparations - Distilled Witch Hazel eye washHealth Condition 1: H28- Cataract in diseases classified elsewhereCTRI/2022/07/043857Stericon Pharma Private Limited72